Dong Lingqiu, Yang Dandan, Qin Aiya, Wang Siqing, Tang Yi, Tan Jiaxing, Qin Wei
Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, China.
Ren Fail. 2025 Dec;47(1):2449580. doi: 10.1080/0886022X.2025.2449580. Epub 2025 Jan 8.
IgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and specific therapeutic methods for IgAN are limited. Telitacicept is a humanized fusion protein composed of a transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor and human IgG.
To evaluate the efficacy and safety of telitacicept in adult patients with IgAN in a real-world study.
Biopsy-proven IgAN patients with 24-hour proteinuria greater than 0.5 g/d who received 240 mg telitacicept weekly were recruited for this study and 1:1:1 matched with patients who received supportive treatment only or immunosuppressive treatment by propensity score matching. The primary outcome was the change from baseline in 24-hour proteinuria over the 3-month follow-up.
Twenty-one patients in each group were enrolled. Telitacicept reduced median proteinuria by 0.72 g/d (54.6%) from baseline, compared with a reduction of 0.18 g/d (20%) in the supportive treatment group and 1.12 g/d (72.1%) in the immunosuppressive treatment group. Preserved eGFR levels were observed in the telitacicept group, whereas eGFR levels decreased in the other two groups. No serious adverse events were observed in the telitacicept treatment group.
Telitacicept may be an effective treatment for IgAN patients by reducing proteinuria and preserving eGFR, and showed a favorable safety profile.
IgA肾病（IgAN）是全球最常见的原发性肾小球疾病，针对IgAN的特异性治疗方法有限。泰它西普是一种由跨膜激活剂和钙调亲环素配体相互作用分子受体与人IgG组成的人源化融合蛋白。
在一项真实世界研究中评估泰它西普治疗成年IgAN患者的疗效和安全性。
本研究纳入经活检证实的24小时蛋白尿大于0.5g/d的IgAN患者，这些患者每周接受240mg泰它西普治疗，并通过倾向评分匹配与仅接受支持治疗或免疫抑制治疗的患者按1:1:1进行匹配。主要结局是随访3个月期间24小时蛋白尿相对于基线的变化。
每组纳入21例患者。泰它西普使蛋白尿中位数较基线降低0.72g/d（54.6%），而支持治疗组降低0.18g/d（20%），免疫抑制治疗组降低1.12g/d（72.1%）。泰它西普组观察到估算肾小球滤过率（eGFR）水平得以保留，而其他两组eGFR水平下降。泰它西普治疗组未观察到严重不良事件。
泰它西普可能是治疗IgAN患者的有效方法，可降低蛋白尿并保留eGFR，且安全性良好。
